Market Cap (In CNY)
4.1 Billion
Revenue (In CNY)
2.17 Billion
Net Income (In CNY)
44.23 Million
Avg. Volume
3.78 Million
- Currency
- CNY
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 7.32-14.3
- PE
- -
- EPS
- -
- Beta Value
- 0.388
- ISIN
- CNE1000026N8
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Weiyi Shen
- Employee Count
- -
- Website
- https://www.starrypharm.com
- Ipo Date
- 2016-03-09
- Details
- Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products comprise levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is based in Xianju, China.
More Stocks
-
UNIOFFICEUniversal Office Automation Limited
UNIOFFICE
-
PSTO
-
AXREFAmarc Resources Ltd.
AXREF
-
NDENF
-
NEIL
-
INTEGHITIntegrated Hitech Ltd
INTEGHIT
-
605577
-
006060HWASEUNG Industries Co.,Ltd.
006060